FDA approves new treatments for thyroid eye disease, eye redness, and myasthenia gravis

The FDA has approved Enspryng for thyroid eye disease, offering a new at-home subcutaneous option. Brytly, a nonprescription eye drop, was also approved for eye redness relief. Additionally, a zilucoplan autoinjector received approval, providing another self-administered treatment for generalized myasthenia gravis. These approvals expand treatment choices for patients.